UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                             -----------------------

                                    FORM 8-K

                                 CURRENT REPORT

                     Pursuant to Section 13 or 15(d) of The
                         Securities Exchange Act of 1934

        Date of report (Date of earliest event reported): September 14, 2005

                            HEALTHRENU MEDICAL, INC.
             (Exact name of registrant as specified in its charter)

             Nevada                    000-21914        84-1022287
   -------------------------------   -------------  ------------------
   (State or other jurisdiction of    (Commission     (IRS Employer
         incorporation)               File Number)   Identification No.)

                 12777 Jones Road, Suite 481, Houston, TX        77070
                 ----------------------------------------        -----
               (Address of Principal Executive Offices)        (Zip Code)

            Our telephone number, including area code: (281) 890-2561
                                                       ---------------

                                 Not Applicable
                                 --------------
          (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of us under any of the following
provisions (see General Instruction A.2. below):

[_]   Written communications pursuant to Rule 425 under the Securities Act (17
      CFR 230.425)

[_]   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)

[_]   Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))

[_]   Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 CFR 240.13e-4(c))


<PAGE>

Section 3 - Securities and Trading Markets

Item 3.02. Unregistered Sales of Equity Securities.

On September 14, 2005 and September 22, 2005, we closed on the sale of our
securities in a private placement. We sold 125 of our Units ("Units") for
$125,000 cash and $114,000 of Units for $114,000 cash on September 14, 2005 and
September 22, 2005, respectively. Each Unit consists of a convertible promissory
note in the principal amount of $1,000 (the "Notes") and two warrants for each
share of our common stock issued upon conversion of the Notes, each warrant to
purchase one share of our common stock at an exercise price per share equal to
125% and 150%, respectively, of the conversion price of the Notes then in effect
upon conversion of the shares of Notes by the stockholder from time to time (the
"Warrants").

The Notes are convertible at the election of the holder thereof, at any time
commencing from and after their date of issuance and for a period of three years
thereafter. The conversion price is equal to 85% of the average closing price of
our common stock on the OTC Bulletin Board for the 10 trading days immediately
preceding the day upon which we receive a conversion notice from the Noteholder.
The shares of Notes are entitled to receive 8% annual interest payable in shares
of our common stock. The Warrants are exercisable for shares of our common stock
at any time beginning on the date of conversion of the Notes and ending on
October 31, 2009 and are subject to adjustment for anti-dilution purposes.

For the $125,000 of Units sold on September 14, 2005, the total offering price
and the total commissions paid to broker-dealers were $125,000 and $18,750,
respectively. For the $114,000 of Units sold on September 22, 2005, the total
offering price and the total commissions paid to broker-dealers were $114,000
and $17,100, respectively. Broker-dealer commissions consisted of:

      o     a commission of 12% of the gross offering proceeds raised by the
            broker-dealer;

      o     a non-accountable expense allowance of 3% of the gross offering
            proceeds raised by the broker-dealer; and

      o     warrants to purchase that number of shares of our common stock as
            equals 10% of the number of shares of common stock that would be
            issuable to investors in the offering assuming conversion of the
            Notes at the closing date, with an exercise price equal to 110% of
            their conversion prices on such date, a term of four years and all
            other terms substantially the same as those of other warrants
            issuable to investors in the offering.

Such fees were deducted from offering proceeds to the extent applicable.

Issuance of the securities was exempt from registration pursuant to Rule 506 of
Regulation D promulgated under Section 4(2) of the Securities Act. The Units
were sold to accredited investors in a private placement without the use of any
form of general solicitation or advertising. The underlying securities are
"restricted securities" subject to applicable limitations on resale.
<PAGE>

Section 9 - Financial Statements and Exhibits

Item 9.01.  Financial Statements and Exhibits.

(c)      EXHIBITS

         10.1     Form of 8% Convertible Notes.(1)

         10.2     Form of 125% Warrant.(1)

         10.3     Form of 150% Warrant.(1)

----------
(1) Filed as Exhibits 10.1, 10.2 and 10.3 to our Form 8-K filed with the
Securities and Exchange Commission on September 9, 2005, and incorpoated herein
by reference.


<PAGE>

                                   SIGNATURES

      Pursuant to the requirements of the Securities Exchange Act of 1934, we
have duly caused this report to be signed on our behalf by the undersigned
hereunto duly authorized.

Date:  September 27, 2005


                                HEALTHRENU MEDICAL, INC.
                                (Registrant)


                                By: /s/  Robert W. Prokos
                                    --------------------------------------------
                                    Name:  Robert W. Prokos
                                    Title: President and Chief Executive Officer
{"company-data": {"conformed-name": "HEALTHRENU MEDICAL INC", "cik": "0000791118", "assigned-sic": "6770", "irs-number": "841022287", "state-of-incorporation": "CO", "fiscal-year-end": "0930"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-21914", "film-number": "051107823"}, "business-address": {"street1": "7255 E. QUINCY AVENUE", "street2": "SUITE 550", "city": "DENVER", "state": "CO", "zip": "80237", "phone": "303-437-9434"}, "mail-address": {"street1": "P O BOX 620", "city": "TAMPA", "state": "FL", "zip": "33601"}, "former-company": [{"former-conformed-name": "AGTSPORTS INC", "date-changed": "19930616"}, {"former-conformed-name": "ULTRATECH KNOWLEDGE SYSTEMS INC", "date-changed": "19920703"}, {"former-conformed-name": "AMERICAN MERGER CONTROL INC /CO/", "date-changed": "19900823"}]}
UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                             -----------------------

                                    FORM 8-K

                                 CURRENT REPORT

                     Pursuant to Section 13 or 15(d) of The
                         Securities Exchange Act of 1934

        Date of report (Date of earliest event reported): September 14, 2005

                            HEALTHRENU MEDICAL, INC.
             (Exact name of registrant as specified in its charter)

             Nevada                    000-21914        84-1022287
   -------------------------------   -------------  ------------------
   (State or other jurisdiction of    (Commission     (IRS Employer
         incorporation)               File Number)   Identification No.)

                 12777 Jones Road, Suite 481, Houston, TX        77070
                 ----------------------------------------        -----
               (Address of Principal Executive Offices)        (Zip Code)

            Our telephone number, including area code: (281) 890-2561
                                                       ---------------

                                 Not Applicable
                                 --------------
          (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of us under any of the following
provisions (see General Instruction A.2. below):

[_]   Written communications pursuant to Rule 425 under the Securities Act (17
      CFR 230.425)

[_]   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)

[_]   Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))

[_]   Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 CFR 240.13e-4(c))
Section 3 - Securities and Trading Markets

Item 3.02. Unregistered Sales of Equity Securities.

On September 14, 2005 and September 22, 2005, we closed on the sale of our
securities in a private placement. We sold 125 of our Units ("Units") for
$125,000 cash and $114,000 of Units for $114,000 cash on September 14, 2005 and
September 22, 2005, respectively. Each Unit consists of a convertible promissory
note in the principal amount of $1,000 (the "Notes") and two warrants for each
share of our common stock issued upon conversion of the Notes, each warrant to
purchase one share of our common stock at an exercise price per share equal to
125% and 150%, respectively, of the conversion price of the Notes then in effect
upon conversion of the shares of Notes by the stockholder from time to time (the
"Warrants").

The Notes are convertible at the election of the holder thereof, at any time
commencing from and after their date of issuance and for a period of three years
thereafter. The conversion price is equal to 85% of the average closing price of
our common stock on the OTC Bulletin Board for the 10 trading days immediately
preceding the day upon which we receive a conversion notice from the Noteholder.
The shares of Notes are entitled to receive 8% annual interest payable in shares
of our common stock. The Warrants are exercisable for shares of our common stock
at any time beginning on the date of conversion of the Notes and ending on
October 31, 2009 and are subject to adjustment for anti-dilution purposes.

For the $125,000 of Units sold on September 14, 2005, the total offering price
and the total commissions paid to broker-dealers were $125,000 and $18,750,
respectively. For the $114,000 of Units sold on September 22, 2005, the total
offering price and the total commissions paid to broker-dealers were $114,000
and $17,100, respectively. Broker-dealer commissions consisted of:

      o     a commission of 12% of the gross offering proceeds raised by the
            broker-dealer;

      o     a non-accountable expense allowance of 3% of the gross offering
            proceeds raised by the broker-dealer; and

      o     warrants to purchase that number of shares of our common stock as
            equals 10% of the number of shares of common stock that would be
            issuable to investors in the offering assuming conversion of the
            Notes at the closing date, with an exercise price equal to 110% of
            their conversion prices on such date, a term of four years and all
            other terms substantially the same as those of other warrants
            issuable to investors in the offering.

Such fees were deducted from offering proceeds to the extent applicable.

Issuance of the securities was exempt from registration pursuant to Rule 506 of
Regulation D promulgated under Section 4(2) of the Securities Act. The Units
were sold to accredited investors in a private placement without the use of any
form of general solicitation or advertising. The underlying securities are
"restricted securities" subject to applicable limitations on resale.
Section 9 - Financial Statements and Exhibits

Item 9.01.  Financial Statements and Exhibits.

(c)      EXHIBITS

         10.1     Form of 8% Convertible Notes.(1)

         10.2     Form of 125% Warrant.(1)

         10.3     Form of 150% Warrant.(1)

----------
(1) Filed as Exhibits 10.1, 10.2 and 10.3 to our Form 8-K filed with the
Securities and Exchange Commission on September 9, 2005, and incorpoated herein
by reference.
SIGNATURES

      Pursuant to the requirements of the Securities Exchange Act of 1934, we
have duly caused this report to be signed on our behalf by the undersigned
hereunto duly authorized.

Date:  September 27, 2005

                                HEALTHRENU MEDICAL, INC.
                                (Registrant)

                                By: /s/  Robert W. Prokos
                                    --------------------------------------------
                                    Name:  Robert W. Prokos
                                    Title: President and Chief Executive Officer